Oral administration of heptylphysostigmine in healthy volunteers: a preliminary study.

@article{Unni1994OralAO,
  title={Oral administration of heptylphysostigmine in healthy volunteers: a preliminary study.},
  author={Latha K Unni and Jerilynn Radcliffe and Gloria Latham and Trey P Sunderland and Rub{\'e}n L{\'o}pez Mart{\'i}nez and William A Potter and Robyn E. Becker},
  journal={Methods and findings in experimental and clinical pharmacology},
  year={1994},
  volume={16 5},
  pages={373-6}
}
Heptylphysostigmine (HP) is a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer inhibitory action than the parent compound, physostigmine (Phy). Single (0.1-0.6 mg/kg) and multiple 5-day (0.1-0.3 mg/kg) doses of HP were administered to 21 young normal volunteers. The relationship between logarithmic dose (mg/kg) and peak inhibition of red blood cell (RBC) ChE was linear with dose. In one subject given 0.6 mg/kg of HP, concentration in plasma was 0.68 ng/ml at 2 h… CONTINUE READING